Abstract
Iron supplementation therapy seems almost indispensable in adequate management of the patients with end - stage renal disease on maintenance hemodialysis, since at least one and a half grams iron is considered to be required per year to keep sufficient erythropoiesis. Iron supplementation in conjunction with erythropoietic-stimulating agents is widely carried out as a standard therapy. However, definite diagnosis of iron deficiency in hemodialysis patients is often difficult since serum ferritin levels increase frequently by various reasons including inflammation and malignancy. Although several guidelines to treat anemia of the hemodialysis patients have been proposed, they seem still insufficient and careful clinical observation is required in individual patient to avoid possible complications of iron overload. We, here, reassess the adequate iron supplementation therapy in those patients, and the necessity of new guideline employing recent advances including magnetic resonance imaging – based method (FerriScan) and hemoglobin content per each reticulocyte is also discussed.
Keywords: Erythropoietic-stimulating agents, end-stage renal disease, ferritin, iron, hemodialysis, iron deficiency, iron supplementation, iron overload.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis
Volume: 13 Issue: 3
Author(s): Masanori Shibata and Shinkichi Taniguchi
Affiliation:
Keywords: Erythropoietic-stimulating agents, end-stage renal disease, ferritin, iron, hemodialysis, iron deficiency, iron supplementation, iron overload.
Abstract: Iron supplementation therapy seems almost indispensable in adequate management of the patients with end - stage renal disease on maintenance hemodialysis, since at least one and a half grams iron is considered to be required per year to keep sufficient erythropoiesis. Iron supplementation in conjunction with erythropoietic-stimulating agents is widely carried out as a standard therapy. However, definite diagnosis of iron deficiency in hemodialysis patients is often difficult since serum ferritin levels increase frequently by various reasons including inflammation and malignancy. Although several guidelines to treat anemia of the hemodialysis patients have been proposed, they seem still insufficient and careful clinical observation is required in individual patient to avoid possible complications of iron overload. We, here, reassess the adequate iron supplementation therapy in those patients, and the necessity of new guideline employing recent advances including magnetic resonance imaging – based method (FerriScan) and hemoglobin content per each reticulocyte is also discussed.
Export Options
About this article
Cite this article as:
Shibata Masanori and Taniguchi Shinkichi, Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1871529X1303140129155609
DOI https://dx.doi.org/10.2174/1871529X1303140129155609 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Molecular and Cellular Changes Behind Aortic Valve Stenosis
Current Pharmaceutical Biotechnology Fat Tissue Distribution Changes in HIV-Infected Patients Treated with Lopinavir/Ritonavir. Results of the MONARK Trial
Current HIV Research Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism Polyglandular Autoimmune Syndromes
Current Immunology Reviews (Discontinued) Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Cellular Senescence in Ageing, Age-Related Disease and Longevity
Current Vascular Pharmacology 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Screening and Structure-Activity Relationship of Potential Compounds against Proposed Targets of COVID-19 Infection
Letters in Drug Design & Discovery Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Multiple Drug Targets in the Management of Type 2 Diabetes
Current Drug Targets Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Improvement of Tumor Localization of Photosensitizers for Photodynamic Therapy and Its Application for Tumor Diagnosis
Current Topics in Medicinal Chemistry Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Current Topics in Medicinal Chemistry Inherited Renal Diseases
Current Pediatric Reviews Biomarker Approach Towards Rheumatoid Arthritis Treatment
Current Rheumatology Reviews Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology